BIO-Europe 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences
Biotech companies at BIO‑Europe 2026
Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website
149 biotech companies are at BIO-Europe 2026 — 146 presentations on the program. Most represented: Miltenyi Biomedicine (3 on the program), Atrogi (2 on the program), CellNBetter (2 on the program). 129 of them have their own page in this guide. As of Nov 10, 2026.
Track
Top represented
Showing 1–16 of 149 organizations
| Organization | BIO-Europe 2026 Attendance |
|---|---|
Miltenyi Biomedicine Bergisch Gladbach, Germany | |
Clinical-stage company of the Miltenyi Group developing CAR-T and other cell therapies for cancer and autoimmune disease. | Panel Tue Nov 10 10:00–10:45 Accelerating Access to Innovative Therapies for European Patients Through Integrated Decision-Making How approval, benefit reviews and pricing decisions could run side by side instead of one after another, so European patients get new medicines sooner. Panel Tue Nov 10 09:30–09:55 From Clinical Success to Commercial Readiness: Strategic Lessons in Bringing Advanced Therapies to Patients Lessons from preparing cell and gene therapies for launch by planning manufacturing, approval and reimbursement alongside the clinical trials. Talk Wed Nov 11 09:30–09:55 Bridging Therapeutic Areas: Navigating the Oncology–Autoimmune Convergence in Cellular Therapies How cell therapies built for cancer are moving into autoimmune disease, and how trial endpoints, risk expectations and teams must change. |
A Atrogi Stockholm, Sweden | |
Develops oral small molecules for type 2 diabetes and obesity that increase glucose uptake in skeletal muscle. | Panel Tue Nov 10 16:00–16:45 AI and Innovation in Clinical Trials: Transforming Operations and Accelerating Development How AI can speed clinical trials, from drafting trial plans and finding patients to computer-simulated patients that cut how many real ones are needed. Panel Tue Nov 10 10:00–10:45 Cardiometabolic innovations beyond GLP-1 – Where are we now? Which drug approaches beyond GLP-1 medicines are drawing attention for obesity, diabetes and heart disease risk, and where money and partnerships are going. |
CellNBetter Daejeon, South Korea | |
Panel Tue Nov 10 14:00–14:30 Korea's Next Wave: Biotech Innovators to Watch Korean biotechs present work spanning drug formulation, safety testing, the microbiome, mRNA and gene therapy delivery, and engineered toxins for cosmetic use. Talk Wed Nov 11 10:10–10:20 Technologies and Tools: CellNBetter Inc. An automated multi-organ cell culture platform, with ready-made kits and analysis, that replaces manual drug testing before clinical trials. | |
Genmab Copenhagen, Denmark | |
Danish biotech developing antibody therapeutics for cancer and other diseases. | Panel Mon Nov 9 13:00–14:00 Navigating partnering and business development in a shifting global landscape How funding conditions, treatment trends and geopolitics are shaping partnerships and acquisitions between drug and biotech companies, with real deal examples. Panel Tue Nov 10 10:45–11:15 From Partnering Pioneer to Global Biotech Leader: The Next Chapter for European Innovation How Genmab grew from licensing its discoveries to others into a global company selling its own drugs, and what European biotechs can learn. |
Stanford spinout using AI-driven target and drug discovery around extrachromosomal circular DNA in cancer, with a European hub in Berlin. | Panel Tue Nov 10 09:30–09:55 Biopharma Ecosystem Germany: Spotlight on Innovation Drivers Ready for Take-Off Five teams from Germany's biotech scene, which spans university research, companies, drug manufacturing and healthcare, show their work and its impact. Panel Tue Nov 10 15:00–15:25 Inside the Incubator: What It Really Takes to Build a Biotech Company Today What incubators backed by big drug companies look for in young biotechs, and how they help founders with money, advice and partners. |
Tubulis Munich, Germany | |
Develops antibody-drug conjugates for solid tumors using proprietary conjugation technologies. | Talk Mon Nov 9 09:00–10:00 Building Your BD Career: What Really Moves the Needle What it takes to build a career in drug licensing and partnership deals, from scientific and financial skills to credibility and contacts. Keynote Mon Nov 9 12:00–13:00 Building a competitive and impactful European biotech community: Perspectives from the European Life Sciences Coalition, Argenx and Tubulis How Europe can keep biotech talent, money and companies at home by drawing in big investors, speeding regulation and building stronger stock markets. Ecosystem InnovationBusiness of Biotech Panel Mon Nov 9 15:00–15:25 |
Develops oral small-molecule allosteric inhibitors for chronic inflammation, fibrosis and cancer, led by an oral inhibitor of IL-1β production. | Panel Wed Nov 11 10:30–10:55 Building a Clinical Strategy for Rare Disease Therapeutics How bold trial designs, such as adaptive trials and basket trials testing one drug in several diseases, can help a first-of-its-kind therapy succeed. Panel Wed Nov 11 09:00–09:25 Learning from Failures and Successes in Clinical Trials What failed and successful clinical trials teach about designing and running better trials, using real examples. |
CT Cellula Therapeutics Epalinges, Switzerland | |
Swiss cell therapy biotech spun out of the University of Geneva. | Panel Wed Nov 11 10:30–10:55 Building a Clinical Strategy for Rare Disease Therapeutics How bold trial designs, such as adaptive trials and basket trials testing one drug in several diseases, can help a first-of-its-kind therapy succeed. Panel Wed Nov 11 11:00–11:45 Capital with a Mission: Investing Beyond Traditional Venture Models How mission-driven and foundation investors fund neglected diseases such as glioblastoma and neuroblastoma that venture capital passes over, focusing on Switzerland. |
Biocytogen Beijing, China | ◆Gold Sponsor |
Offers humanized mouse models, preclinical services and fully human antibody discovery, and licenses antibody assets including bispecifics and ADCs. | Talk Tue Nov 10 09:00–09:25 RenSuper Workstation: An AI-Driven Antibody Discovery Platform From Target to Antibody Leads in Clicks How Biocytogen combines immunized mice, DNA sequencing, AI screening and lab tests to find fully human antibody candidates in months, not years. |
3billion Seoul, South Korea | |
Rare-disease genetic testing company whose genome analysis is re-run as new disease genes are described, until a patient is diagnosed. | Talk Mon Nov 9 15:15–15:30 Drug Discovery and Development: 3billion How a rare disease genetic testing company is using its large store of genome and patient data to find drug targets with AI. |
AB AAVantgarde Bio Milan, Italy | |
Develops dual-AAV gene therapies for inherited retinal diseases such as Usher syndrome and Stargardt disease. | Panel Wed Nov 11 10:00–10:45 Envisioning the future of ophthalmology What new data show about treatments for retinal disease, glaucoma and other eye conditions, and where investors see the most promise. |
Ability Biotherapeutics Montreal, Canada | |
Develops conditionally activated and multispecific antibodies for cancer and autoimmune diseases, using a generative AI discovery platform. | Talk Mon Nov 9 09:00–10:00 Building Your BD Career: What Really Moves the Needle What it takes to build a career in drug licensing and partnership deals, from scientific and financial skills to credibility and contacts. |
Develops and markets medicines for neurological and rare diseases, including Parkinson's disease psychosis and Rett syndrome. | Panel Tue Nov 10 09:00–09:45 Networks or neurons: What’s next in CNS dealmaking? What is driving recent deals between biotechs and larger drug companies for brain and nervous system drugs, which remain hard to develop. |
Aerska Dublin, Ireland | |
Develops RNAi medicines for neurodegenerative diseases, using antibody shuttles to carry them across the blood-brain barrier. | Panel Tue Nov 10 09:00–09:45 Networks or neurons: What’s next in CNS dealmaking? What is driving recent deals between biotechs and larger drug companies for brain and nervous system drugs, which remain hard to develop. |
AT Agomab Therapeutics Ghent, Belgium | |
Develops organ-restricted small molecules for fibrotic diseases, including fibrostenosing Crohn's disease and idiopathic pulmonary fibrosis. | Panel Mon Nov 9 14:00–14:45 Voices from the IPO Class of ’25/’26: What’s Next? Leaders of biotechs that listed on the stock market in 2025 and 2026 describe life after going public and the hurdles they face. |
Alia Therapeutics Trento, Italy | |
Italian gene editing start-up working on one-time treatments that correct inherited diseases at the level of the gene. | Chair Tue Nov 10 09:20–09:30 |
Find buyers from biotech companies
Tell us what you sell and we’ll find the people at these biotech companies most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse BIO-Europe 2026 by
Organization type
Track
Everyone
Not affiliated with or endorsed by BIO-Europe or its organizers. Submit a correction